PDCD1 and neoplasm: To investigate if these ligands may reduce activation in exhausted tumor-infiltrating MAIT cells, and thus if MAIT cells might respond to checkpoint blockade therapy, we stimulated MAIT cells with anti-CD3 and anti-CD28 antibodies in the presence or absence of neutralizing antibodies to PD-1.